Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...
EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...
Hosted on MSN2d
Wall Street Analysts See a 67.54% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?CRISPR Therapeutics AG (CRSP) closed the last trading session at $48.92, gaining 1.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
New gene therapies developed using CRISPR gene editing offer the promise of treating or even curing debilitating diseases.
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.
7don MSN
In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...
CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...
Okomera announces Bpifrance funding to develop and standardize novel CRISPR screening assay to accelerate drug discovery in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback